Autolus Therapeutics plc (6A3A.F)
- Previous Close
3.9400 - Open
3.7800 - Bid 3.7400 x --
- Ask 3.8000 x --
- Day's Range
3.7800 - 3.7800 - 52 Week Range
1.6200 - 7.1000 - Volume
1,000 - Avg. Volume
101 - Market Cap (intraday)
1.005B - Beta (5Y Monthly) 1.93
- PE Ratio (TTM)
-- - EPS (TTM)
-1.1200 - Earnings Date May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.61
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.
www.autolus.comRecent News: 6A3A.F
Performance Overview: 6A3A.F
Trailing total returns as of 4/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6A3A.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6A3A.F
Valuation Measures
Market Cap
991.56M
Enterprise Value
817.62M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
415.39
Price/Book (mrq)
9.67
Enterprise Value/Revenue
481.52
Enterprise Value/EBITDA
-5.22
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-25.35%
Return on Equity (ttm)
-101.61%
Revenue (ttm)
1.7M
Net Income Avi to Common (ttm)
-208.38M
Diluted EPS (ttm)
-1.1200
Balance Sheet and Cash Flow
Total Cash (mrq)
239.57M
Total Debt/Equity (mrq)
200.82%
Levered Free Cash Flow (ttm)
-125.13M
Research Analysis: 6A3A.F
Company Insights: 6A3A.F
6A3A.F does not have Company Insights